Colorectal lung metastases: Results of surgical excision

doi:10.1016/0003-4975(92)91435-C

The Annals of Thoracic Surgery

Volume 53, Issue 5, May 1992, Pages 780-786

https://doi.org/10.1016/0003-4975(92)91435-C Get rights and content

Abstract

Between 1960 and 1988, 139 consecutive patients underwent pulmonary resection for metastatic colorectal carcinoma. Median interval between colon resection and lung resection was 34 months. Ninety-eight patients (70.5%) had a solitary metastasis. Wedge excision was performed in 68 patients, lobectomy in 53, lobectomy plus wedge excision in 9, bilobectomy in 4, and pneumonectomy in 5. Operative mortality was 1.4%. Localized extrapulmonary colorectal cancer was also resected in 20 patients. Median follow-up was 7 years (range 1 to 20.4 years). Overall 5- and 20-year survival was 30.5% and 16.2%, respectively. Five-year survival for patients with solitary metastasis was 36.9%, as compared with 19.3% for those with two metastases (p < 0.05) and 7.7% for those with more than two (p < 0.01). Patients with normal carcinoembryonic antigen had a 5-year survival of 46.8% versus 16.0% for patients with increased levels (p < 0.01). Five-year survival for patients with resected extrapulmonary disease was 30.0% versus 30.7% for those without extrapulmonary cancer (p = notsignificant). Repeat thoracotomy for recurrent metastases was done in 19 patients. Five-year survival after the second lung resection was 30.2%. We conclude that resection of colorectal lung metastases is safe and effective, that resectable extrapulmonary disease does not necessarily contraindicate pulmonary resection, and that repeat thoracotomy is warranted in selected patients with recurrent colorectal lung metastases.

References (34)

JK Mansel et al.
Pulmonary resection of metastatic colorectal adenocarcinoma: a ten-year experience
Chest
(1986)
JO Wright et al.
Results of pulmonary resection for metastatic lesions
J Thorac Cardiovasc Surg
(1982)
CF Mountain et al.
Surgery for pulmonary metastasis' a twenty-year experience
Ann Thorac Surg
(1984)
EW Wilkins et al.
Pulmonary resection for metastatic neoplasms in the lung
Am J Surg
(1978)
PC Adkins et al.
Thoracotomy on the patient with previous malignancy: metastasis or new primary?
J Thorac Cardiovasc Surg
(1968)
A Blalock
Recent advances in surgery
N Engl J Med
(1944)
PM McCormack et al.
Resected pulmonary metastases from colorectal cancer
Dis Colon Rectum
(1979)
WG Cahan et al.
Therapeutic pulmonary resection of colonic carcinoma metastatic to lung
Dis Colon Rectum
(1974)
LB Chuksi et al.
The surgical management of solitary pulmonary metastasis
Surg Gynecol Obstet
(1972)
E Pihl et al.
Lung recurrence after curative surgery for colorectal cancer
Dis Colon Rectum
(1987)

SJ Brister et al.

Contemporary operative management of pulmonary metastases of colorectal origin

Dis Colon Rectum

(1988)

T Goya et al.

Surgical resection of pulmonary metastases from colorectal cancer: ten-year follow-up

Cancer

(1989)

ER Sauter et al.

Improved survival after pulmonary resection of metastatic colorectal carcinoma

J Surg Oncol

(1990)

J Scheele et al.

Pulmonary resection for metastatic colon and upper rectum cancer: is it useful?

Dis Colon Rectum

(1990)

KA Kern et al.

Surgical treatment of pulmonary metastases

CF Morrow et al.

Surgical resection for metastatic neoplasms of the lung

Cancer

(1980)

N Wilking et al.

Surgical resection of pulmonary metastases from colorectol adenocarcinoma

Dis Colon Rectum

(1985)

Cited by (271)

Recurrent and Metastatic Colorectal Cancer
2019, Shackelford's Surgery of the Alimentary Tract: 2 Volume Set
Colorectal cancer relapse, although often complex in presentation, can best be considered and categorized as resectable for possible cure or not. Where the former is possible, long-term survival can be achieved, specifically for isolated lesions in the liver, lungs, and locoregional sites. For relapses in local and regional sites, results appear to be improved with the use of a multispecialty approach, including external beam radiation therapy (EBRT) plus concomitant 5-fluorouracil-based chemotherapy (even in previously irradiated patients), in addition to maximal resection and intraoperative radiation therapy (IORT). This approach can be done safely and can lead to long-term disease-free and overall survival. These results may be further enhanced by the introduction of new systemic adjuvant therapies with different mechanisms of actions that are aimed at reducing the risk of systemic failure. When re-recurrence occurs, salvage may be possible. R0 resection remains the primary determinant of outcome. When presented with cases of diffuse disease, clinical efforts should not be abandoned but rather refocused on improving quality of life.
Lung Metastases
2019, Abeloff’s Clinical Oncology
In this chapter, we provide a comprehensive review of the pathogenesis, features, diagnostic evaluation, management, survival, and complications from lung metastasis. Lung metastasis may arise due to a combination of dietary influences, genetic and immunologic changes using normal cellular processes to assist in metastatic spread. Computed tomography with or without positron emission tomography is most frequently used to detect lung metastases since MRI is less sensitive than these modalities. Patients with isolated or oligometastatic disease can be considered for definitive management, including radiofrequency ablation (RFA), stereotactic radiation therapy, and surgical resection with non-surgical interventions typically offered for unresectable tumors or poor surgical candidates. Primary tumor types that commonly have lung metastasis include colon carcinoma, renal cell carcinoma, sarcoma, melanoma, head and neck squamous cell carcinoma, germ cell tumors, breast cancer, and giant cell tumor of bone, and survival after treatment is highly dependent on the primary site. Common complications of metastatic disease include malignant pleural effusions, managed with indwelling catheters or sclerotic agents, and bronchial obstructions, managed with endobronchial stenting, photodynamic therapy, and radiation therapy.
Surgery for pulmonary metastases from colorectal cancer: Predictive factors for survival
2016, Revue des Maladies Respiratoires
Le cancer colorectal représente la 3^e cause de mortalité par cancer : 5 % des patients vont développer des métastases pulmonaires. Le concept de chirurgie des cancers oligométastatiques est basé sur l’objectif d’un contrôle local optimal de la maladie.
À ce jour, aucun essai contrôlé randomisé ne valide la chirurgie de résection des métastases pulmonaires des patients oligométastatiques porteurs d’un cancer colorectal contrôlé localement. Cependant, de nombreuses séries, le plus souvent rétrospectives, rapportent des survies prolongées chez des patients très sélectionnés, allant de 45 à 65 % à 5 ans dans les séries les plus récentes. Les facteurs consensuels de bon pronostic établis sont : un intervalle libre supérieur à 36 mois, un nombre de métastases ≤ 3, un taux d’antigène carcino-embryonnaire normal et l’absence d’envahissement ganglionnaire médiastino-hilaire.
Environ 20 à 40 % des patients vont présenter des récidives pulmonaires probablement liées à l’existence de micro-métastases indétectables. Ainsi, des travaux expérimentaux sont actuellement menés pour développer de nouvelles techniques de traitement, telles que la perfusion pulmonaire isolée, la radiofréquence et la stéréotaxie.
La résection des métastases pulmonaires de cancers colorectaux peut améliorer la survie et le contrôle de la maladie chez des patients bien sélectionnés.
Colorectal cancer is the 3rd commonest cause of death from cancer: 5% of patients will develop lung metastases. The management of oligometastatic disease is based on the objective of optimal local control.
To date, no results from randomized control trials support the resection of pulmonary metastases in oligometastastic colorectal cancer patients. However, numerous series, mainly retrospective, report long-term survival for highly selected patients, with 5-year survival ranging from 45 to 65% in the most recent series. The consensual predictive factors of a good prognosis are: a disease free-interval > 36 months, a number of metastases ≤ 3, a normal level of carcino-embryonic antigen and the absence of hilar or mediastinal lymph node involvement.
Around 20 to 40% of patients will develop recurrence, probably linked to the presence of undetectable micrometastases. Therefore, experimental work is being undertaken to develop new treatment techniques such as isolated lung perfusion, radiofrequency ablation and stereotactic radiation therapy.
Highly selected patients suffering from colorectal cancer lung metastases could benefit from resection with improved survival and disease-control.
Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases
2016, International Journal of Radiation Oncology Biology Physics
Citation Excerpt :
Oligometastatic disease, metastatic deposits limited in number, is a situation where initial local therapy may be preferred. (4). Indeed, several retrospective studies have demonstrated that pulmonary metastasectomy, including the use of video assisted thoracic surgery (VATS) and removing 1 to 5 lesions, prolongs overall survival (OS) in carefully selected patients (5-12). Current national guidelines recommend definitive local therapy as an alternative to systemic therapy if it can be safely performed in well-selected patients with limited pulmonary metastases from melanoma, non-small cell lung cancer (NSCLC), and colon cancer (13-15).
Pulmonary oligometastases have conventionally been managed with surgery and/or systemic therapy. However, given concerns about the high cost of systemic therapy and improvements in local treatment of metastatic cancer, the optimal cost-effective management of these patients is unclear. Therefore, we sought to assess the cost-effectiveness of initial management strategies for pulmonary oligometastases.
A cost-effectiveness analysis using a Markov modeling approach was used to compare average cumulative costs, quality adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) among 3 initial disease management strategies: video-assisted thoracic surgery (VATS) wedge resection, stereotactic body radiation therapy (SBRT), and systemic therapy among 5 different cohorts of patient disease: (1) melanoma; (2) non-small cell lung cancer adenocarcinoma without an EGFR mutation (NSCLC AC); (3) NSCLC with an EGFR mutation (NSCLC EGFRm AC); (4) NSCLC squamous cell carcinoma (NSCLC SCC); and (5) colon cancer. One-way sensitivity analyses and probabilistic sensitivity analyses were performed to analyze uncertainty with regard to model parameters.
In the base case, SBRT was cost effective for melanoma, with costs/net QALYs of $467,787/0.85. In patients with NSCLC, the most cost-effective strategies were SBRT for AC ($156,725/0.80), paclitaxel/carboplatin for SCC ($123,799/0.48), and erlotinib for EGFRm AC ($147,091/1.90). Stereotactic body radiation therapy was marginally cost-effective for EGFRm AC compared to erlotinib with an incremental cost-effectiveness ratio of $126,303/QALY. For colon cancer, VATS wedge resection ($147,730/2.14) was the most cost-effective strategy. Variables with the greatest influence in the model were erlotinib-associated progression-free survival (EGFRm AC), toxicity (EGFRm AC), cost of SBRT (NSCLC SCC), and patient utilities (all histologies).
Video-assisted thoracic surgery wedge resection or SBRT can be cost-effective in select patients with pulmonary oligometastases, depending on histology, efficacy, and tolerability of treatment and patient preferences.
Survival improvement for patients with metastatic colorectal cancer over twenty years
2023, npj Precision Oncology
Percutaneous Computed Tomography (CT)-Guided Localization with Indocyanine Green for the Thoracoscopic Resection of Small Pulmonary Nodules
2023, Journal of Clinical Medicine

View all citing articles on Scopus

^☆: Presented at the Thirty-eighth Annual Meeting of the Southern Thoracic Surgical Association, Orlando, FL, Nov 7–9, 1991.

View full text

Original articleColorectal lung metastases: Results of surgical excision☆

Abstract

Chest

J Thorac Cardiovasc Surg

Ann Thorac Surg

Am J Surg

J Thorac Cardiovasc Surg

Recent advances in surgery

N Engl J Med

Resected pulmonary metastases from colorectal cancer

Dis Colon Rectum

Therapeutic pulmonary resection of colonic carcinoma metastatic to lung

Dis Colon Rectum

The surgical management of solitary pulmonary metastasis

Surg Gynecol Obstet

Lung recurrence after curative surgery for colorectal cancer

Dis Colon Rectum

Contemporary operative management of pulmonary metastases of colorectal origin

Dis Colon Rectum

Surgical resection of pulmonary metastases from colorectal cancer: ten-year follow-up

Cancer

Improved survival after pulmonary resection of metastatic colorectal carcinoma

J Surg Oncol

Pulmonary resection for metastatic colon and upper rectum cancer: is it useful?

Dis Colon Rectum

Surgical treatment of pulmonary metastases

Surgical resection for metastatic neoplasms of the lung

Cancer

Surgical resection of pulmonary metastases from colorectol adenocarcinoma

Dis Colon Rectum

Original article
Colorectal lung metastases: Results of surgical excision☆